^
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 2wk
    No biomarker
    Malignant Pleural Mesothelioma
    pemetrexed
    Sensitive
    :
    A1
    No biomarker
    Malignant Pleural Mesothelioma
    carboplatin + pemetrexed
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    bevacizumab
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    cisplatin + pemetrexed
    Sensitive
    :
    A2
    No biomarker
    Mesothelioma
    GC
    Sensitive
    :
    A2
    No biomarker
    Mesothelioma
    bevacizumab
    Sensitive
    :
    A2
    No biomarker
    Mesothelioma
    cisplatin + raltitrexed
    Sensitive
    :
    A2
    No biomarker
    Mesothelioma
    nivolumab
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    carboplatin + raltitrexed
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    GC
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Malignant Pleural Mesothelioma
    vinorelbine tartrate
    Sensitive
    :
    A2
    BRCA1 mutation
    Mesothelioma
    rucaparib
    Sensitive
    :
    C1
    BAP1 mutation
    Mesothelioma
    tazemetostat
    Sensitive
    :
    C2
    PD-L1 expression
    Malignant Pleural Mesothelioma
    nivolumab
    Sensitive
    :
    C3
    WT1 expression
    Malignant Pleural Mesothelioma
    nivolumab + galinpepimut-S
    Sensitive
    :
    C3
    TMB-L
    Malignant Pleural Mesothelioma
    PD1 inhibitor
    Resistant
    :
    C3
    TMB-L
    Malignant Pleural Mesothelioma
    PD-L1 inhibitor
    Resistant
    :
    C3
    PD-L1 underexpression
    Malignant Pleural Mesothelioma
    PD1 inhibitor
    Resistant
    :
    C3
    BAP1 negative + BRCA1 mutation
    Mesothelioma
    rucaparib
    Sensitive
    :
    C3
    BAP1 negative
    Mesothelioma
    rucaparib
    Sensitive
    :
    C3
    MRE11A mutation
    Mesothelioma
    olaparib
    Sensitive
    :
    C3
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES